Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease
In the field of Hodgkin's lymphoma, many new data have been collected during the last decade both on the cell of origin of this disease and on more effective therapies to cure the majority of pa tients even in the advanced stages. Therefore, it seems to be justi fied to compile these new data in a special volume of Recent Re sults in Cancer Research. This volume summarizes the contribu tions presented at the First International Symposium on Hodgkin's Disease that took place in Cologne (FRG) on October 2-3, 1988. There is little doubt that the Hodgkin and Reed-Sternberg (H and RS) cells and their variants represent the malignant population in Hodgkin's lymphoma; however, there is still a fierce debate as to the possible cell of origin of Hand RS cells. Many of the problems confounding earlier research into this question were related to the difficulty or virtual impossibility, of obtaining purified populations of Hand RS cells. Most of the recent progress stems from the establishment of permanent cell lines of Hand RS cells in culture.
Annals of Oncology
None
Recombinant Antibodies for Cancer Therapy
Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of...
Cancer Immune Therapy
Cure or life with cancer? What can be achieved by cancer immune therapy? The past decade has seen substantial advancements in tumor immunology. Much of the new knowledge has been translated into new strategies for cancer treatment and into clinical trials. Some of these trials herald future breakthroughs, others have been disappointing and have prompted intensive search for alternatives.Major contributors to the field summarize the knowledge on the molecular and cellular mechanisms of tumorigenesis, critically review the instruments of the immune system that might be exploited for therapy, and discuss the clinical experiences with the different immune therapy concepts. Researchers in the fields of immunology, tumor biology and medicine will highly appreciate this up-to-date volume for evaluating future research activities.
Tumor Antigens Recognized by T Cells and Antibodies
Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies. In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens. The discovery of tumor antigens c
Cancer Immunology
This publication provides a comprehensive account of the known groups of human tumour antigens, and the immune effector cells involved in tumour rejection. Chapters dealing with all the major groups of human tumour antigens are included, covering differentiation antigens, testes-associated antigens, CEA, mucin, viral antigens, anti-idiotypic antibodies as antigens, and fusion proteins. The role of heat shock proteins as mediators of tumour immunity is discussed and consideration is given to the immune mechanisms which mediate tumour rejection in both human and animal systems. The application of antibody targeting to identify cancers, and the mechanisms by which tumours evade immune detection and/or destruction is covered in detail. Although the focus of this publication is experimental, as with other recent publications progress in clinical immunotherapy is included in some detail, to provide postgraduate and post-doctoral scientists with in-depth reviews of the field.
Tumor-Associated Antigens
The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies. The result is a must-have for biologists and oncologists in science, clinics and industry.
Non-Hodgkin Lymphoma
This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.
